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Alzheimer's disease (AD) is a neurodegenerative disease and main form of dementia, char-
acterized by progressive cognitive decline and detrimental consequences in both personal-
family and global level. Within this narrative review, we provide recent molecular aspects of 
Tau, a microtubule AD-associated protein as well as amyloid beta, involved in AD pathophys-
iology. Moreover, we provide additional emerging data from basic research as well as clinical 
studies indicating an implicating role of gastrointestinal microbiota (GI-M), including Helico-
bacter pylori infection (Hp-I), in AD pathophysiology. Likewise, we identify through a molecu-
lar prism the current evidence of AD pathogenesis as well as its linkage with GI-M and em-
phasizing the role of Hp-I. All in all, additional large-scale studies are required for the further 
clarification of AD pathophysiology and its connection with GI-M and Hp-I, so as novel thera-



















Alzheimer's disease (AD) is the major cause of dementia characterized by the accu-
mulation of amyloid beta (Aβ) protein, the hyperphosphorylation of tau protein, and neuroin-
flammation, thought to lead to neuronal loss and synaptic dysfunction (1). AD is estimated to 
affect worldwide approximately 46.8 million people over the age of 60, having a rising ten-
dency (2–4); its incidence and prevalence rise exponentially with increasing age particularly 
in the western societies (5), except preventive strategies are developed (2). The predictions 
regarding the prevalence of the disease, led the World Health Organization (WHO) to de-
scribe AD as a “fast-growing epidemic” (6), as a result of its prediction that the number of af-
fected people will triple by 2050 (7). 
The economic consequences as well as the traumatic burden for both patients and 
caregivers are enormous. The outcome is fatal and patients develop with the time impaired 
cognition with parallel continuously deteriorated ability to carry out daily activities and onset 
of neuropsychiatric symptoms (8). The most characteristic symptom at the initial phase of the 
disease is the loss of short-term memory (9). During disease progression, the clinical mani-
festations are further expanded and include speaking problems, sudden changes in mood, 
depression and severe orientation problems (9,10). The later stages of AD are characterized 
by complete withdraw from family and social activities and finally, loss of body functions that 
ultimately lead to death. Importantly, the constantly increasing life expectancy due to major 
improvements in life quality and successful treatment of previously incurable diseases, rep-
resent a critical challenge for ageing-related syndromes (11). Especially for AD, there is a 
massive psychological as well as the mentioned economic burden for both patients and their 
families, which is reflected to the society (12).  
Therefore, the utmost goal of the research community is to identify effective therapeu-
tic strategies that do not only provide symptomatic relief (13), but also to intervene in the mo-
lecular mechanisms involved in  the pathophysiology of this disease, that is complex and not 
yet fully elucidated. In the present narrative review, we aimed to provided new molecular 
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links between AD, gastrointestinal microbiota and Helicobacter pylori infection involved in the 
disease pathophysiology. 
 
Alzheimer’s disease and molecular data  
       
AD typical histopathological findings include the extracellular senile plaque formation 
of amyloid-β peptide (Αβ) and the intracellularly accumulating Neurofibrillary Tangles (NFTs) 
of hyperphosphorylated tau (14). 
 Generally, regarding Aβ deposition involved in senile plaques formation (15), the pro-
teolyctic cleavage of the Amyloid Precursor Protein (APP) by β- and γ-secretases leads to 
the formation of this small peptide (16,17), with its length ranging from 38- up to 43-amino 
acids. Even though the vast majority of the produced peptides have very fast turnover and 
are quickly degraded, the 42-amino acid long version (Aβ42) is highly aggregation-prone and 
exhibits enhanced toxicity (18). Inside the amyloid plaques, Aβ is aggregated and thereby 
forming not only large fibrils, but also smaller insoluble oligomeric formations (19). Important-
ly, these amyloid plaques are usually surrounded by degenerating neurons and an increased 
number of activated microglia, thereby indicating an inflammatory response (20). 
 Likewise, regarding the implication of tau protein in AD etiology and progression, the 
intracellular deposition of hyperphosphorylated tau aggregates, leads to the formation of 
NFTs and Paired Helical Filaments (PHFs) (21,22).  
 
Tau-related molecular data  
  
Tau is a microtubule (MT)-associated protein involved in both the health and disease 
of neurons. In humans, the Microtubule Associated Protein tau gene (MAP) is transcribed 
predominantly throughout the Central Nervous System (CNS) and produces a long pre-
mRNA that contains 16 exons (23). Specifically, six isoforms of tau are expressed predomi-
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nantly in the CNS due to differences regarding the number of the 29-amino acid residue near 
the aminoterminal region (N-terminal projection domain) as well as in the presence of 3- or 4-
repeat domains close to the carboxy-terminal insert (ΜΤ Binding Repeat Domain, RD) (24). 
Being the major functional role, the interaction of tau with the MTs is mediated through the 
electrostatic interactions between the positively charged RD and the negatively charged MT 
surface (25). The reduction of the tau-MT affinity is achieved through phosphorylation of tau, 
which under healthy conditions is a tightly regulated process (24,26). 
The major hypothesis linking AD to the observed hyperphosphorylation in AD patients 
is the loss of this tight regulation for tau phosphorylation, which leads the protein to a higher 
phosphorylation state and consequently detaches from MTs and starts aggregating (27). This 
is mostly based on the observation that in PHFs from AD patients tau is found to be hyper-
phosphorylated in epitopes that are not present in healthy subjects (28–30). Even though tau 
can also be found to be hyperphosphorylated in conditions not related to AD (31), it is widely 
accepted that abnormal phosphorylation is a major (but not the exclusive) factor contributing 
to tau aggregation. 
Patient-derived as well as in vitro-assembled tau filaments demonstrate the typical for 
amyloids cross-β structure (32,33), with the core consisting of about 90 amino acids within 
the RD region. As this part of the protein is also responsible for binding to MTs, tau aggrega-
tion and MT-interaction are considered as two mutually exclusive processes (34,35). Addi-
tionally, while the RD is the core of tau filaments, the N- and C-terminal parts are forming the 
characteristic “fuzzy coat” that surrounds the aggregation core (36,37). 
The exact mechanism of tau-induced neurotoxicity remains unclear. A reasonable 
hypothesis is the loss of tau function due to hyperphosphorylation and aggregation. Howev-
er, tau knockout mice do not demonstrate significantly overt phenotypes (38), most probably 
because other MAPs compensate the loss of tau function. Another proposed mechanism is 
the mislocalization of tau into post-synaptic spines and thereby leading to synaptic dysfunc-
tion (39). However, the most accepted scenario for the tau-mediated toxicity observed in AD 
is the gain of toxic function for the aggregated species. Even though initially the NFTs were 
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suggested to be the detrimental factor for the pathological phenotypes in neurons, there is 
growing evidence towards the significance of smaller oligomeric tau species. This is mostly 
based on the establishment of several experimental tau models that develop toxic pheno-
types due to the presence of aggregates, but in the absence of fibrillar tau (40). However, the 
determination of the exact species responsible for the tau-induced toxic effects is extremely 
challenging, mostly due to the great complexity in preparation and assay read-out heteroge-
neity among several experimental efforts. 
Additionally, the sequential deposition of aggregated tau species throughout the 
brain, combined with the elevated levels of tau in the cerebrospinal fluid (CSF) before AD 
symptoms occur (41), the affected brain areas, and the symptoms, led to the “tau spreading” 
hypothesis. According to this model, misfolded tau trans-cellularly spreads from initially af-
fected brain areas even to long distant neuronal clusters (42), thereby propagating the dis-
ease-related pathology. This process has been recapitulated in murine systems through in-
jection of patient-derived material or in vitro generated tau fibrils (43–46). 
Specifically, the mentioned increased detection of tau in the CSF in various forms 
(full-length, differentially phosphorylated, cleaved etc.) is a well-established observation in 
AD (47). Since CSF-tau is also found in non-demented patients with acute brain injury or 
stroke (48), release of tau from cells was initially empirically interpreted as a result of cell 
death. However, the levels of phosphorylated or non-phosphorylated tau in the CSF of AD 
patients are reproducibly higher compared to adjusted controls with intact cognition (49–52) 
and the detection precedes the occurrence of the symptoms (41). Moreover, over the last 
years there has been a vast number of scientific studies regarding the active release of tau 
from cells (53) and it is firmly established that this occurs even in healthy neurons (54). 
These observations, combined with the “tau spreading” hypothesis as a determining factor 
for disease progression, eventually raised questions regarding a potentially active mecha-
nism for tau secretion. As tau does not contain a signal peptide sequence, its secretion 
seems to follow other pathways, collectively referred to as “Unconventional Protein Secre-
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tion” (UPS) (55,56) and more specifically the proposed pathways for tau are divided either in 
Type I or Type III UPS-dependent mechanisms (57–59). 
 
Aβ- related data: infection hypothesis 
 
 Regarding Aβ and AD, although the implication in pathogenesis is well established, a 
previously thought causative relationship has been questioned; Aβ brain depletion therapies 
have mostly failed, thereby signifying further efforts to investigate novel mechanisms in order 
to clarify the pathophysiology of the disease and introduce new interventional and/or preven-
tive strategies. In this respect, the "infection hypothesis" was recommended, though received 
little attention. Nevertheless, recent data indicate that Aβ is an antimicrobial peptide with 
broad-spectrum antimicrobial properties acting against bacteria, fungi, and viruses (60). In-
deed, relative data indicate that microbial infections increase the synthesis of Aβ and the lat-
ter appears to be an innate immune defense antimicrobial peptide, which utilizes fibrillation to 
protect the host from variable pathogens. Moreover, brain infections often result in augment-
ed amyloidogenic processing of the amyloid-β protein precursor and subsequent fibrillary 
aggregates of Aβ (61). The Aβ oligomers exhibit strong and broad-spectrum antimicrobial 
actions by inducing fibrils, which entrap infectious pathogens and disrupt cell membranes 
(62), while Aβ overexpression in experimental models leads to increased resistance to infec-
tion from viruses and bacteria (63,64). Therefore, the antimicrobial role of Aβ may explain 
why increased rates of infection have been observed in some of the AD clinical trials that de-
pleted Aβ. Even though the Aβ production might be beneficial on the initial microbial chal-
lenge, potentially has gradually detrimental consequences as the infections turn to chronic 
and the host endeavors to remove the excess Aβ may reduce over time as a result of both 
microbial biofilm formation and microglial senescence (60,65). These data provide evidence 
to an infection hypothesis involved in AD pathophysiology. 
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B. Gastrointestinal microbiota including Helicobacter pylori and AD: molecular data 
 
 
 The gastrointestinal microbiota (GI-M) including Helicobacter pylori (Hp) and brain 
relationship is assumed as a potential pathogenic basis for neurological disorders of pro-
nounced health impact such as AD (66,67); the GI-M-brain axis is critical for maintaining GI 
homeostasis and its dysregulation is involved in various disease states such as AD. Specifi-
cally, the GI-M is considered the principal reservoir of microbes in the human body, contain-
ing trillions of microbes and comprises the highest one among all microbial ecosystems, as it 
encodes approximately 4x106 genes, which represents 150 times more the amount of human 
genes (68). The human GI-M as a vital endocrine “organ” is involved in important functions, 
such as influencing metabolism, inducing trophic and protective effects and instructing innate 
immunity (69). Moreover, several data highlight the role of the GI-M in the development of 
neurodegenerative diseases, and in particular AD; the contribution of GI-M dysbiosis (70) to 
the pathogenesis of AD is well depicted in animal models of AD (71,72). In this regard, there 
is a great deal of impetus for the complete understanding of the pathological function, genetic 
evidence and functional diversity of the GI-M that could result in AD development and the 
detection of relative risk factors (73). 
 Growing clinical evidence (74) discloses that the pathophysiology of several neuro-
degenerative disorders could depend on the GI-M and that the resident commensal microbio-
ta influences neuroinflammation (75). In this regard, in a recent study, fecal samples from 43 
AD patients and equal number of cognitive intact controls were collected.  By using 16S ribo-
somal RNA sequencing technique, fecal microbiota composition was analyzed  and was 
found to be different between the two groups; bacteria taxa such as Bacteroides, Actinobac-
teria, Ruminococcus, Lachnospiraceae, and Selenomonadales were different in AD patients 
from those in controls at taxonomic levels (76). Similar results revealed a study from Japan. 
Fecal samples from demented and non-demented patients were obtained, and the gut mi-
crobiome was assessed by terminal restriction fragment length polymorphism analysis. The 
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analysis disclosed differences in the composition of the gut microbiome; the number of Bac-
teroides (enterotype I) was lower and the number of 'other' bacteria (enterotype III) was 
higher in demented patients. Multivariable analyses demonstrated that the populations of en-
terotype I and enterotype III bacteria were both strongly associated with dementia, inde-
pendent of the traditional dementia biomarkers (77).  Other authors reported that gut micro-
biota (GM) of AD patients revealed decreased microbial diversity and is compositionally dis-
tinct from control participants. Moreover, they found phylum- through genus-wide differences 
in bacterial abundance such as decreased Firmicutes, increased Bacteroidetes, and de-
creased Bifidobacterium in the fecal microbiome of AD patients. Interestingly, the authors al-
so observed correlations between levels of differentially abundant genera and CSF bi-
omarkers of AD like Aβ42/Aβ40, phosphorylated tau (and their ratio) and chitinase-3-like pro-
tein 1 (78). Additional study demonstrated that the ammount of Eubacterium rectale and Bac-
teroides fragilis microorganisms in patients with amyloidosis were significantly reduced com-
pared to the cognitive intact group, whereas the number of Escherichia/Shigella bacteria 
significantly increased, thereby supporting the notion that AD affects the GM (79). Further-
more, a large multicenter study revealed, that AD patients were characterized by significantly 
lower concentrations of cholic acid (primary bile acid) and increased levels of the bacterially 
produced deoxycholic acid (secondary bile acid) as well as of its conjugated forms. The in-
creased deoxycholic to cholic acid ratio (reflection of 7α-dehydroxylation by GM), was strong-
ly associated with cognitive incline (80). Likewise, rising evidence from epidemiologic studies 
and animal models links periodontitis, caused by oral microbiota with AD (81–83). 
Focus on Hp infection (Hp-I), a study from France, assessed both clinical and biologi-
cal data of 53 patients with AD, testing the suggestion that Hp could alter the cognitive status 
by increasing inflammation. Results showed a lower mini-mental state examination score 
(p=0.017), higher plasma interleukin (IL)-1β concentrations (p=0.025) and increased gastric 
atrophy (p=0.020) in infected participants compared to uninfected a higher cognitive impair-
ment in Hp-positive AD patients (84). In cross-sectional study, by analyzing data from the US 
national health and nutrition examination survey, a group from US authors also investigated 
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the correlation between Hp positivity and cognitive performance among US adults. Results 
showed a poorer performance of Hp-positive 60-90 years old participants, regarding verbal 
memory test compared to negative. In addition, 20-59 years old infected non-Hispanic black 
and women performed worse on serial digits learning total errors compared to uninfected. 
This was a strong demonstration that Hp could, in some way, correlate with cerebral function 
even if its causative role is still to be established (85). Other authors, proposed that Hp could 
affect AD by interacting with Galectin-3, a glycan-binding protein implicated in several phys-
iological and pathologic processes, including cell signaling, proliferation, and migration as 
well as in the stimulation of immune response (86). 
Concerning GI-M proteins or metabolites, they might promote neurodegeneration ei-
ther by inducing amyloid development through human proteins or by increasing inflammatory 
reactions to endogenous neuronal amyloids (87). The exposure to bacterial amyloid proteins 
in the GI tract may induce priming of the immune system and promote brain autoimmunity 
(88,89), thereby increasing the immune response to endogenous production of neuronal am-
yloids involved in neurodegeneration (75). 
 The human innate immune system recognizes bacterial amyloid proteins by introduc-
ing many signaling pathways (90), such as the toll like receptor (TLR) 1/2, Nod-like receptor-
3 protein (NLRP3), transcriptional nuclear factor kappa-B (NF-κΒ), innate immune receptor 
CD14, and inducible nitric oxide synthase. Other misfolded proteins induced by bacteria can 
be involved in the tissue destruction and the production of pro-inflammatory cytokines con-
nected with AD development (91), collectively indicating that there are interactions between 
brain protein misfolding and GI-M. 
 Disruption of the intestinal barrier (composed by mucus layer intestinal columnar epi-
thelium and lamina propria) leads to translocation of bacteria (process known as atopobiosis) 
and toxic substances into the bloodstream associated with critically disorders; disruption of 
the intestinal barrier may induce local and systemic injuries playing a role in several disor-
ders such GI tract and liver diseases, as well as in the aging process and in the systemic in-
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flammatory response syndrome, including brain dysfunctions (92). In addition to alterations in 
the GM composition influencing gut permeability (93), the increased amount of bacteria in the 
small intestine also influences permeability, as seen in small intestinal bacterial overgrowth 
(SIBO) and some data indicate an increased SIBO prevalence in AD patients (94). In this re-
spect, Hp-related disorders are also associated with dysmotility-induced gastrointestinal bac-
terial overgrowth (GIBO) that may lead to bacteremia with systemic complications including 
brain disorders (66). GM produces and secretes more than 100 metabolites, but their effects 
on the pathogenesis of AD has only began to be elucidated. Bacterial produced acids like 
(iso)valeric acid, (iso)butyric, propionic, acetic and formic acid have been studied and have 
been shown to affect the pathogenesis of AD by disturbing the activations of microglia and 
astrocyte, functioning inflammatory, and against aggregations of Ab and tau (95). 
 Some additional data indicate that the GI-M could disrupt the integrity of the blood-
brain barrier (BBB) (96,97), thereby possibly contributing to brain pathologies. Additionally, 
GI-M dysbiosis could increase the production of lipopolysaccharides and pro-inflammatory 
cytokines that combined with the activation of T lymphocytes and monocytes have been 
suggested to induce augmented intestinal and BBB permeability. These effects have been 
directly linked to subsequent misfolded proteins increase, axonal injury and neuronal demye-
lination involved in the pathophysiology of AD (98). 
 Regarding the mentioned aberrantly phosphorylated tau playing a central role in AD 
pathophysiology (99), recent data indicate that GI-M-induced metabolite trimethylamine N-
oxide (TMAO) is increased in the CSF of patients with AD and mild cognitive impairment 
(MCI) (69). Moreover, CSF TMAO concentrations are related with CSF biomarkers of AD pa-
thology (phosphorylated tau and Αβ) and neuronal degeneration (total tau, neurogranin, and 
neurofilament light chain protein), offering supplementary support for the role of GI-M in AD 
pathophysiology. In this respect, a healthy diet seems to reduce the risk of AD development 
and experimental bioactive food ingestion appears to reduce neuroinflammation, oxidative 
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stress, Aβ aggregation, and tau hyperphosphorylation with a concomitant cognition im-
provement (100). 
 GI-M and Hp have been shown to affect neurodegenerative processes by promoting 
inflammation, inducing molecular mimicry mechanisms and cerebral accumulation of Aβ pep-
tides. Hp is one of the identified bacterial pathogens in humans, which its role is principally 
as a pathogen or a commensal (101). Hp-I has been shown to influence GI-M composition, 
thereby promoting dysbiosis, which represents a potential significant topic for Hp-related GI 
pathologies and AD development (102–104).  
In this respect, in a mouse model mimicking human AD, transgenic APP/PS1 mice 
were compared to wild-type histologically, microbiologically and behaviorally. The results 
showed impaired spatial learning and memory appeared in APP/PS1 mice, which was further 
aggravated 2 months later. The brain lesions were consistent immunohistochemically with 
amyloid plaques. Moreover, AD histological and behavioral manifestations in the APP/PS1 
mice were found to be correlated with a specific GM state and microbiota diversity of 
APP/PS1 mice decreased with increased age; abundance of Helicobacteraceae and Desul-
fovibrionaceae at the family level and Odoribacter and Helicobacter at the genus level in-
creased significantly in APP/PS1 mice than in WT mice, while Prevotella abundance in WT 
mice was significantly higher than in APP/PS1 mice (105). Moreover, two large-scale clinical 
surveys demonstrate that infectious burden, among others including Hp, is associated with 
worse cognitive performance in multiethnic cohort Northern Manhattan Studies (106,107). 
Moreover, regarding the impact of Hp-I on vascular dementia, Hp positive patients are char-
acterized by higher pro-inflammatory cytokine levels (tumor necrosis factor (TNF)-α, IL-1β 
and IL-12) and worse scores of Montreal and Mini-Mental State Examination cognitive evalu-
ations (108); the aforementioned pro-inflammatory cytokines appear to be involved in AD 
pathophysiology (109). Likewise, another recent study reported that Hp seropositivity is di-
rectly associated with incidence of all-cause and AD dementia and with AD mortality (110). 
Regarding the latter findings, by introducing the histologic analysis of gastric mucosa biopsy 
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for the documentation of active Hp-I, our own studies reported that Hp eradication regimen is 
associated with a lower 5-year mortality rate in AD patients (8). Comparable data are also 
obtained for glaucoma (defined as “ocular” AD) that shares similar risk factors and pathoge-
netic mechanisms with AD (111,112). Besides, two recent published review articles summa-
rized additional substantial studies linking AD with Hp and GI-M  (2,102). Three main mech-
anisms include the possibility of Hp to enter in the brain via the oral-, nasal-, olfactory-
pathways or through the aforementioned disrupted BBB, thereby leading to neurodegenera-
tion; a fourth mechanism includes the possibility of Hp-related toxic agents to access the 
brain via the GI tract fast retrograde neural pathway and thus inducing brain neurodegenera-
tion pathologies (2). Other pathogens, which have been proven isolated in AD human brain, 
mostly in post mortem studies, include Chlamydophila pneumoniae, Borrelia burgdorferi, and 
other spirochetes or herpes simplex virus type 1 (94). 
 Regarding the BBB dysfunction, inflammatory mediators including cytokines and 
chemokines produced by Hp-I, induce BBB disruption. For instance, Hp-I releases the men-
tioned TNF-α, acting at a distance and involving in BBB disruption via matrix metalloprotein-
ases upregulation (2).  Likewise, Hp-induced Vacuolating cytotoxin (VacA) displays chemo-
tactic activities to the bone marrow-derived mast cells (BMDMCs) and stimulates BMDMCs 
to produce proinflammatory cytokines that damage the BBB (113). Beyond the activated 
mast cells releasing vascular endothelial growth factor (VEGF), IL-8, chymase, tryptase and 
mast cell growth factor connected to Hp-I, mast cells themselves release mediators including 
histamine, IL-8, tryptase, and VEGF, that disturb the BBB (114). Mast cell degranulation ac-
celerates the secretion of these potent mediators, which can orchestrate neuroinflammation 
and affect the BBB integrity, thereby contributing to neurodegenerative processes (66). 
 Finally, regarding the mentioned phosphorylated tau involved in AD pathophysiology 
(99), in vitro and animal models verified that apart from Aβ42, Hp induces tau hyperphosphor-
ylation, which is directly linked to the AD-associated neurodegeneration. Specifically, incuba-
tion of Hp filtrated on mouse neuroblastoma N2a cells overexpressing AβPP caused an 
augmented production of presenilin-2 (a component of the γ- secretase enzyme complex in-
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volved in the production of Aβ) and Aβ42 (115). In the same study, intraperitoneal injection 
of Hp filtrate in rats induced spatial learning and memory deficits, abnormal hippocampal 
dendritic spine maturation, and augmented presenilin-2 and Aβ42 in rat brain hippocampus 
and cortex. However, Escherichia coli filtrate injection did not influence cognitive function in 
rats and Aβ production in rats and cells (115). Moreover, Hp filtrate induced substantial tau 
hyperphosphorylation at several AD-related tau phosphorylation sites in mouse neuroblas-
toma N2a cells via activation of glycogen synthase kinase-3β (116). Equally, intraperitoneal 
injection of Hp filtrate in rats resulted in noteworthy tau hyperphosphorylation in hippocampal 
areas of rat brain, while microglial activation and raised brain/plasma cytokine levels were 
not observed. These studies appear to provide evidence of the association between Hp-I and 
AD-like Aβ and phospho-tau pathology, indicating that Hp eradication may be beneficial in 
the tauopathy prevention. 
 Collectively, viewing the aforementioned data, it seems that molecular data of GI-M 
and Hp-I may contribute to the pathophysiology of AD and thus further large-scale relative 
studies are necessary to elucidate this field. 
 
C. Concluding remarks 
 
AD is a global burden with rising tendency and affects mainly the elderly population. 
Since the consequences are disastrous for affected families and societies, the necessity of 
further investigation for elucidation of pathogenicity and development of novel therapies, is of 
enormous significance. Mechanistically, hallmarks of disease in CNS are regarded the extra-
cellular amyloid plaque formation and tau protein hyperphosphorylation. The “infectious hy-
pothesis” gains ground lately, since Aβ is considered as antimicrobial peptide. The GI-M, in-
cluding Hp which its role is mainly as a pathogen or a commensal, through a plethora of 
emerging data from basic research as well clinical studies reinforce the aforementioned hy-
pothesis; the interplay between brain and GI-M constitutes an axis, where immune and en-
docrine stimuli play a central key role for shaping homeostasis or leading to dysbiosis and 
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neurodegeneration. All in all, a new challenging era of understanding the complex patho-
physiology of AD and impact of GI-M/Hp on neurodegeneration has just began. The future is 
expected to be exciting and further large-scale studies are warranted, so as a substantiation 
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